LatAm List – Memed is a leading healthtech platform from Brazil that recently raised a $4.5M Series B led by DNA Capital, along with repeat investor Redpoint eventures. Other past investors include Monashees Capital and Qualcomm Ventures.
Memed’s vision is to transform the traditional practice of creating handwritten medical prescriptions into 100% digital and intelligent prescriptions in Brazil, ensuring patient safety and increasing efficiency for doctors, patients, and pharmacies.
“The path we are following is a long one and it is only possible to reach our goal with the help of the best partners in the market. We see at DNA Capital , together with current partners, the opportunity to add a partner with great experience in the health area, opening new doors and accelerating our growth plan in the market,” said Ricardo Moraes, CEO at Memed.
DNA Capital considers this investment as an important step to consolidate Memed as the main platform for transforming the medical prescription experience.
“DNA Capital has acted globally in its practice of venture capital and sees, in this investment, a great opportunity to transform the health market. Solving the problems related to electronic prescription of medicines and ensuring that patients can have security in their treatments is a challenging mission and a great opportunity. Memed is driving the health sector for the future and we want to help it in this process,” said Luiz Henrique Noronha, Partner at DNA Capital.
Memed has over 80,000 registered doctors, more than 10 million prescriptions, and generated $273M (R$1.2B) in prescriptions in 2019.